A need for speed
twoXAR's aims to slash lead prioritization time with disease-mapping algorithm
Bioinformatics play twoXAR Inc. aims to condense years of wet-lab compound discovery and lead prioritization into minutes. The company has created an in silico platform that uses machine learning to build a mathematical disease model and predict the efficacy of compounds in that disease.
twoXAR's computational platform, DUMA, is based on CEO Andrew A. Radin's work in biomedical informatics at Stanford University and serves as a drug discovery tool internally, to identify